SCHEMBL3083392

SCHEMBL3083392

CN(C)CC(=O)N1CCC(c2ccc(N)c(C3=CCCCC3)c2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 7/20 0.61
CSF1R P07333 14/20 0.59
CYP3A4 P08684 7/20 0.59
BMPR1B O00238 2/20 0.59
PLK4 O00444 2/20 0.59
STK25 O00506 2/20 0.59
RIOK3 O14730 2/20 0.59
CHEK1 O14757 2/20 0.59
GAK O14976 2/20 0.59
DCLK1 O15075 2/20 0.59
MUSK O15146 2/20 0.59
EPHB6 O15197 2/20 0.59
PDPK1 O15530 2/20 0.59
MAP3K13 O43283 2/20 0.59
DAPK3 O43293 2/20 0.59
MAP3K7 O43318 2/20 0.59
NUAK1 O60285 2/20 0.59
JAK2 O60674 2/20 0.59
ULK1 O75385 2/20 0.59
ERN1 O75460 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL3173783 0.93 KIT (0.55) KITCSF1RCYP3A4BMPR1BPLK4
Trifluoroacetic Acid SCHEMBL3173721 0.93 KIT (0.54) KITCSF1RCYP3A4BMPR1BPLK4
SCHEMBL3090414 0.90 CSF1R (0.62) KITCSF1RCYP3A4BMPR1BPLK4
SCHEMBL2912407 0.89 KIT (0.58) KITCSF1RCYP3A4BMPR1BPLK4
SCHEMBL2907517 0.87 CSF1R (0.49) KITCSF1RCYP3A4BMPR1BPLK4
SCHEMBL2913951 0.87 CSF1R (0.61) KITCSF1RCYP3A4BMPR1BPLK4
SCHEMBL2916006 0.86 CSF1R (0.56) KITCSF1RCYP3A4BMPR1BPLK4
SCHEMBL25541526 0.84 CSF1R (0.65) KITCSF1RCYP3A4BMPR1BPLK4
Trifluoroacetic Acid SCHEMBL3173774 0.83 KIT (0.53) KITCSF1RCYP3A4BMPR1BPLK4
Trifluoroacetic Acid SCHEMBL3173697 0.83 KIT (0.52) KITCSF1RCYP3A4BMPR1BPLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210290784-A1 POSITRON EMISSION TOMOGRAPHY (PET) RADIOTRACERS FOR IMAGING MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R) IN NEUROINFLAMMATION THE JOHNS HOPKINS UNIVERSITY 2021-09-23 US claimed
EP-1807077-B1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-11-23 EP claimed
US-7662837-B2 4-cyano-1H-imidazole-2-carboxylic acid {2-cyclohex-1-enyl-4-[1-(2-dimethylamino-acetyl)-piperidin-4-yl]-phenyl}-amide; protein tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent JANSSEN PHARMACEUTICA N.V. (BE) 2010-02-16 US claimed
EP-1807077-A2 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-18 EP claimed
US-20060189623-A1 Inhibitors of c-fms kinase ILLIG CARL R 2006-08-24 US claimed
US-20060148812-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2006-07-06 US claimed
WO-2006047277-A2 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO claimed
US-20210290784-A1 POSITRON EMISSION TOMOGRAPHY (PET) RADIOTRACERS FOR IMAGING MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R) IN NEUROINFLAMMATION THE JOHNS HOPKINS UNIVERSITY 2021-09-23 US disclosed
EP-3813890-A1 POSITRON EMISSION TOMOGRAPHY (PET) RADIOTRACERS FOR IMAGING MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R) IN NEUROINFLAMMATION The Johns Hopkins University (US) 2021-05-05 EP disclosed
US-10806737-B2 Compounds and methods for the targeted degradation of fetal liver kinase polypeptides ARVINAS OPERATIONS, INC. (US) 2020-10-20 US disclosed
US-20180256586-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES ARVINAS OPERATIONS, INC. 2018-09-13 US disclosed
US-9526731-B2 Method of inhibiting C-KIT kinase JANSSEN PHARMACEUTICA NV (BE) 2016-12-27 US disclosed
EP-1807077-B1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-11-23 EP disclosed
WO-2007124369-A2 METHOD OF INHIBITING C KIT KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-01 WO disclosed
EP-1807077-A2 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-18 EP disclosed
US-20070149572-A1 METHOD OF INHIBITING FLT3 KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-06-28 US disclosed
US-20060281788-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR JANSSEN PHARMACEUTICA, N.V. (BE) 2006-12-14 US disclosed
US-20060189623-A1 Inhibitors of c-fms kinase ILLIG CARL R 2006-08-24 US disclosed
US-20060148812-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2006-07-06 US disclosed
WO-2006047277-A2 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189623-A1 Inhibitors of c-fms kinase MUSK, TYK2, FES KIT 125/4885CSF1R 34/4885CYP3A4 3871/4885
US-20180256586-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES MDM2, CRBN, FLT3 KIT 557/4885CSF1R 806/4885CYP3A4 4122/4885
US-20060281788-A1 SYNERGISTIC MODULATION OF FLT3 KINASE USING A FLT3 INHIBITOR AND A FARNESYL TRANSFERASE INHIBITOR FLT3, MCL1, CSF1R KIT 70/4885CSF1R 3/4885CYP3A4 2047/4885
US-20060148812-A1 Inhibitors of c-fms kinase MUSK, TYK2, FES KIT 125/4885CSF1R 34/4885CYP3A4 3871/4885
US-20210290784-A1 POSITRON EMISSION TOMOGRAPHY (PET) RADIOTRACERS FOR IMAGING MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R) IN NEUROINFLAMMATION CSF1R, CSF3R, CMKLR1 KIT 315/4885CSF1R 1/4885CYP3A4 4736/4885
US-10806737-B2 Compounds and methods for the targeted degradation of fetal liver kinase polypeptides MDM2, CRBN, FLT3 KIT 557/4885CSF1R 806/4885CYP3A4 4122/4885
US-20070149572-A1 METHOD OF INHIBITING FLT3 KINASE FLT3, PLK1, PHKG1 KIT 192/4885CSF1R 149/4885CYP3A4 3994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.